Featured Post

Respirology | APSR Respiratory Medicine Journal

Image
stage 3 small cell lung cancer life expectancy :: Article Creator Small-Cell Lung Cancer: Symptoms, Causes, Tests, Treatment, And More - WebMD When cells of the lung start growing rapidly in an uncontrolled way, the condition is called lung cancer This disease can affect any part of the lung, and it's the leading cause of cancer deaths in both women and men in the United States, Canada, and China. There are two main types of lung cancer. Small-cell lung cancer (SCLC), sometimes called small-cell carcinoma, causes about 10%-15% of all lung cancer. Non-small-cell lung cancer (NSCLC) causes the rest. There are two main types: Small-cell carcinoma (oat cell cancer) Combined small-cell carcinoma Both include many types of cells that grow and spread in different ways. They're named according to what the cells look like under a microscope. Small-cell lung cancer differs from non-small-cell lung cancer in some key ways. Small-cell lung...

Lung Granuloma: Symptoms, Causes, Treatment, Diagnosis, Cancer



bronchopulmonary :: Article Creator

Vitamins & Supplements Center

Considering taking a vitamin or supplement to treat Bronchopulmonary+Dysplasia? Below is a list of common natural remedies used to treat or reduce the symptoms of Bronchopulmonary+Dysplasia. Follow the links to read common uses, side effects, dosage details and read user reviews for the drugs listed below.

13 results found for Bronchopulmonary+Dysplasia

Learn about User Reviews and read IMPORTANT information about user generated content

Conditions of Use and Important Information: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.© Therapeutic Research Faculty 2018.


Early Ibuprofen Not Beneficial For Preemies With Patent Ductus Arteriosus

For extremely preterm infants, the risk for death or moderate or severe bronchopulmonary dysplasia is not significantly lower among those receiving early treatment for patent ductus arteriosus (PDA) with ibuprofen versus placebo, according to a study published in the Jan. 25 issue of the New England Journal of Medicine.

Samir Gupta, M.D., from Sidra Medicine in Doha, Qatar, and colleagues conducted a multicenter, randomized, double-blind, placebo-controlled trial assessing early ibuprofen treatment (≤72 hours after birth) for a large PDA (diameter ≥1.5 mm with pulsatile flow) in extremely preterm infants. Overall, 326 and 327 infants were assigned to receive ibuprofen and placebo, respectively; 324 and 322 had data available for outcome analyses. A composite of death or moderate or severe bronchopulmonary dysplasia evaluated at 36 weeks of postmenstrual age was the primary outcome.

The researchers found that a primary outcome event occurred in 69.2 and 63.5% of infants in the ibuprofen and placebo groups, respectively (adjusted risk ratio, 1.09; 95% confidence interval [CI], 0.98 to 1.20; P = 0.10); 13.6 and 10.3% of infants, respectively, died (adjusted risk ratio, 1.32; 95% confidence interval, 0.92 to 1.90). Moderate or severe bronchopulmonary dysplasia occurred in 64.2 and 59.3% of the ibuprofen and placebo groups, respectively, among the infants who survived to 36 weeks of postmenstrual age (adjusted risk ratio, 1.09; 95%t confidence interval, 0.96 to 1.23).

"Our results are broadly consistent with those of other studies of early targeted treatment of PDA with ibuprofen that have not shown a convincing benefit with respect to clinical outcomes," the authors write.

More information: Samir Gupta et al, Trial of Selective Early Treatment of Patent Ductus Arteriosus with Ibuprofen, New England Journal of Medicine (2024). DOI: 10.1056/NEJMoa2305582

Jill L. Maron, Patent Ductus Arteriosus—To Close or Not to Close?, New England Journal of Medicine (2024). DOI: 10.1056/NEJMe2313738

2024 HealthDay. All rights reserved.

Citation: Early ibuprofen not beneficial for preemies with patent ductus arteriosus (2024, January 25) retrieved 4 February 2024 from https://medicalxpress.Com/news/2024-01-early-ibuprofen-beneficial-preemies-patent.Html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.






Comments

Popular Posts

Model Monday's: Diana Moldovan

“Teaching a pandemic in real time, part 2 . Princeton professors share how they incorporate the study - Princeton University” plus 1 more

Preventing, controlling spread of animal diseases focus of forum at Penn State - Pennsylvania State University